Efficacy News and Research

RSS

SARS-CoV-2 variants containing L452R spike mutation more resistant to antibody-mediated neutralization

A team of scientists from Frankfurt, Germany, has recently explored the efficacy of vaccine- or infection-induced antibodies and therapeutic monoclonal antibodies in neutralizing kappa and delta variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 Aug 2021

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

Researchers determine the structure of receptor involved in type 2 diabetes and other pathologies

Researchers from the University of Southern California, Merck & Co., Skoltech, MIPT, UCLA, and the Université de Sherbrooke have determined the structure of the human leukotriene B4 receptor 1, involved in inflammatory, infectious, allergic, and tumorigenic diseases.

12 Aug 2021

Nanotechnology may help improve treatment for colorectal cancer and melanoma

University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.

12 Aug 2021

New research offers hope to increase efficacy of immunotherapy for lung cancer

Lung cancer is the leading cause of cancer-related death. Current treatments employ immunotherapy, often in combination with chemotherapy, but benefits to patients remain slight.

11 Aug 2021

Small NIH clinical trial shows that new monoclonal antibody can prevent malaria

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite.

11 Aug 2021

COVID-19 vaccines offer better protection than natural immunity alone

Now, the U.S. Centers for Disease Control and Prevention (CDC) reports that among people who were previously infected with SARS-CoV-2, those who were still unvaccinated are more likely to be reinfected than those fully vaccinated after prior infection.

11 Aug 2021

Plant-based virus-like particle vaccine induces durable immune response against SARS-CoV-2 variants

Scientists from Germany and Belgium have recently described the immunogenicity of a plant-based virus-like particle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine induces robust antibody and T cell responses for at least 6 months. Moreover, the vaccine demonstrates potent neutralizing efficacy against the B.1.1.7, B.1.351, and P1 variants of SARS-CoV-2.

11 Aug 2021

Both mRNA vaccines protect against symptomatic disease with SARS-CoV-2 Delta variant

A new study demonstrates that the two mRNA vaccines have widely varying efficacies against the SARS-CoV-2 Delta variant.

10 Aug 2021

Study defines SARS-CoV-2 antibodies associated with neutralization and effector functions

A new study explores the polyclonal antibody response to SARS-CoV-2 in greater detail.

10 Aug 2021

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

A new study reports a more rapid method of viral inactivation in an effort to increase the appeal of inactivated viral vaccines against the COVID-19 pandemic.

10 Aug 2021

Natural vs. vaccine-induced COVID-19 immunity

A new paper discusses the protection offered by immunity against COVID-19 following vaccination as compared to natural infection.

10 Aug 2021

Researchers create a computational model to evaluate drug delivery through inhalers

Increased air pollution in recent years has not only contributed to deteriorating environmental conditions in cities across the globe.

10 Aug 2021

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

A potential new treatment for mast cell cancers reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

10 Aug 2021

Tiny tumbling soft robots could precisely deliver drugs to central nervous system

Would you let a tiny MANiAC travel around your nervous system to treat you with drugs? You may be inclined to say no, but in the future, "magnetically aligned nanorods in alginate capsules" (MANiACs) may be part of an advanced arsenal of drug delivery technologies at doctors' disposal.

10 Aug 2021

New platform can quickly identify common mutations on the SARS-CoV-2 virus

Researchers at the University of Colorado Boulder have developed a platform which can quickly identify common mutations on the SARS-CoV-2 virus that allow it to escape antibodies and infect cells.

10 Aug 2021

Penn study discovers a targetable vulnerability in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) cells can be destroyed and kept from multiplying by inhibiting the HDL cholesterol receptor SCARB1, according to research from the Perelman School of Medicine at the University of Pennsylvania.

10 Aug 2021

Pilot study assesses antibody response to third COVID-19 vaccine dose in kidney transplant recipients

A pilot study has begun to assess the antibody response to a third dose of an authorized COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine.

10 Aug 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

Evaluation of COVID-19 risk among international travelers in the UK for safety purposes

A high risk of transmission of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, is associated with international travel.

9 Aug 2021

Efficacy News and Research

SARS-CoV-2 variants containing L452R spike mutation more resistant to antibody-mediated neutralization

Camelid nanobody anti-SARS-CoV-2 drug candidates

Researchers determine the structure of receptor involved in type 2 diabetes and other pathologies

Nanotechnology may help improve treatment for colorectal cancer and melanoma

New research offers hope to increase efficacy of immunotherapy for lung cancer

Small NIH clinical trial shows that new monoclonal antibody can prevent malaria

COVID-19 vaccines offer better protection than natural immunity alone

Plant-based virus-like particle vaccine induces durable immune response against SARS-CoV-2 variants

Both mRNA vaccines protect against symptomatic disease with SARS-CoV-2 Delta variant

Study defines SARS-CoV-2 antibodies associated with neutralization and effector functions

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

Natural vs. vaccine-induced COVID-19 immunity

Researchers create a computational model to evaluate drug delivery through inhalers

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

Tiny tumbling soft robots could precisely deliver drugs to central nervous system

New platform can quickly identify common mutations on the SARS-CoV-2 virus

Penn study discovers a targetable vulnerability in clear cell renal cell carcinoma

Pilot study assesses antibody response to third COVID-19 vaccine dose in kidney transplant recipients

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

Evaluation of COVID-19 risk among international travelers in the UK for safety purposes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News